Coronavirus / COVID

Phase 2 results include a large cohort of seniors in the study.

For the first time, prescribed users at suspected risk of COVID-19 can receive rapid results from home.

The investigational vaccine is being reported as 95% effective.

SARS-CoV-2 outbreaks on 16 different mink farms in the Netherlands have been identified showing transmission between humans and minks.

The data comes from a phase 1/2 trial with the CoronaVac vaccine.

A survey of clinicians found that despite planning for resource limitations during the coronavirus 2019 (COVID-19) pandemic, clinicians still faced difficult decisions at bedside.

New study finds casual links between obese people and the potential for a higher risk of COVID-19 infection

Non-pharmaceutical interventions (NPIs) are not only effective against COVID-19, but also respiratory infections.

Phase 2 data hints the immune response-modulating therapy could play a role in burdened hospital settings.

Further evidence demonstrating the lack of efficacy of hydroxychloroquine as a treatment for coronavirus disease 2019 (COVID-19) was detailed in a new randomized, multicenter, blinded, placebo-controlled study published in JAMA.

The Vanderbilt Professor of Preventive Medicine shares thoughts on the first potential COVID-19 vaccine, at a time of record new daily cases.

The biotechnology has reached it COVID-19 case accrual mark, and announced plans to submit data to an independent review board.

Findings from Michigan show financial, mental health, and cardiopulmonary impacts are prevalent in patients 2 months after hospital care.

Blood pressure medication adherence should continue for patients with COVID-19, and atrial fibrillation and atrial flutter can worsen outcomes in hospitalized COVID-19 patients.

Large cohort study quantifies risk for hospital admission for COVID-19 among healthcare workers and members of their households.

The anti-inflammatory drug infliximab may have a role in treating COVID-19, according to a new study examining how a key enzyme influences viral entry and gut inflammation.

Patients with rheumatic diseases do not appear to face heightened risk from COVID-19, even if they are taking immunosuppressant medications, new data indicates.

The country halted the Sinovac investigational vaccine due to what was being reported as a serious adverse event.

Alzheimer’s disease, dementia, and genetic variations in areas key to viral infection are risk factors for severe COVID-19 a new study suggests.

Bamlanivimab should be administered as soon as possible after a positive test, and within 10 days of developing symptoms, Eli Lilly said.

The federal agency announced Novavax’s, NVX-CoV2373, was granted this designation.

The new research letter also highlights a concerning rate of infection among Latino patients.

The company is still awaiting its threshold for total COVID-19 infections in its 44,000-patient assessment. Nonetheless, they believe they have made history.

A new survey shows just 2% of children with rheumatic disease reported COVID-19 positive test results or symptoms through early May.